A comparative analysis of SARS-CoV-2 antivirals in human airway models characterizes 3CL(pro) inhibitor PF-00835231 as a potential new treatment for COVID-19

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological agent of Coronavirus Disease 2019 (COVID-19). There is a dire need for novel effective antivirals to treat COVID-19, as the only approved direct-acting antiviral to date is remdesivir, targeting the viral polymerase comp...

Descripción completa

Detalles Bibliográficos
Autores principales: de Vries, Maren, Mohamed, Adil S, Prescott, Rachel A, Valero-Jimenez, Ana M, Desvignes, Ludovic, O’Connor, Rebecca, Steppan, Claire, Devlin, Joseph C, Ivanova, Ellie, Herrera, Alberto, Schinlever, Austin, Loose, Paige, Ruggles, Kelly, Koralov, Sergei B, Anderson, Annaliesa S., Binder, Joseph, Dittmann, Meike
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457613/
https://www.ncbi.nlm.nih.gov/pubmed/32869028
http://dx.doi.org/10.1101/2020.08.28.272880

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457613/
https://www.ncbi.nlm.nih.gov/pubmed/32869028
http://dx.doi.org/10.1101/2020.08.28.272880

Ejemplares similares